This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by del Rosario, J. F. Articles by Kocoshis, S. A. Search for Related Content PubMed PubMed Citation Articles by del Rosario, J. F. Articles by Kocoshis, S. A. Social Bookmarking                         What's this?

Retrospective Analysis of Alternate-Day Predn'isone Maintenance Therapy for Crohn's Disease

Susan R. Orenstein, MD

Deborah A. Neigut

Vicki Giarrusso, RN

Nancy Wolfson, RN

Samuel A. Kocoshis, MD

Department of Pediatrics, Division of Pediatric Gastroenterology, University of Pittsburgh School of Medicine, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania

We reviewed the medical records of 98 children with Crohn's disease followed at Children's Hospital of Pittsburgh from 1983 to 1993 to evaluate the merits of alternate-day prednisone (AD) maintenance therapy once initial remission was achieved. Of the 98 children, 35 had adequate data recorded for eligibility to the study. Of these, 11 were in the AD group and 24 were in a group whose maintenance regimen did not include prednisone (NO). The dependent variables were frequency of flares and linear growth over time. AD therapy reduced mean symptomatic flares (0.23 ± 0.1 vs 0.69 +0.14 flares/patient/year; p=0.04) over a 2-year follow-up period but did not delay significantly the onset of a flare after remission was achieved (16.5 ± 3.4, vs 13.4 ± 1.8 months; p=0.4). Site of disease involvement had no impact on frequency of flares. Fewer patients in the AD group experienced flares, but this finding did not achieve statistical significance (4/11, 36%, vs 17/24, 71%; p = 0.0⁷). Linear growth, measured in height percentile and growth velocity (cm/year), was not significantly reduced by the second year of either therapy. This small retrospective study suggests that AD prednisone therapy may be effective in reducing symptomatic flares in Crohn's patients without a resultant inhibition of linear growth.

Clinical Pediatrics, Vol. 37, No. 7, 413-419 (1998)
DOI: 10.1177/000992289803700703


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?